Guardant360 CDx submitted for regulatory approval in Japan
Guardant360 CDx submitted for regulatory approval in Japan with advanced solid tumors TOKYO, Feb. 3, 2021 /PRNewswire/ -- Guardant Health Japan, an affiliate of Guardant Health Asia, Middle East & Africa (AMEA) has announced that it has submitted its application to the Ministry of Health, Labour and Welfare (MHLW) for regulatory approval of Guardant360 CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling (CGP) in patients with advanced solid cancerous tumors. "I am delighted to announce that we have submitted the regulatory application for Gu...
Source: finanznachrichten.de